Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20359–371 (2023).
Google Scholar
Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384705–716 (2021).
Google Scholar
Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 3881002–1014 (2023).
Google Scholar
Hansen, D. K. et al. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium. J. Clin. Oncol. 412087–2097 (2023).
Google Scholar
Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398314–324 (2021).
Google Scholar
San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389335–347 (2023).
Google Scholar
Sidana, S. et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood 14585–97 (2025).
Google Scholar
Bar, N. et al. Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2−4 prior lines of therapy: a matching-adjusted indirect comparison. Curr. Med. Res. Opin. 401597–1603 (2024).
Google Scholar
Nadeem, O. et al. Early safety and efficacy of CAR-T cell therapy in precursor myeloma: results of the CAR-PRISM study using ciltacabtagene autoleucel in high-risk smoldering myeloma. Blood 1441027 (2024).
Google Scholar
Wenqiang Yan, C. D. et al. BCMA CAR-T therapy as first-line consolidation treatment in transplant-ineligible patients with newly-diagnosed multiple myeloma: an open label, single-arm, phase 2 study (CAREMM-001). https://ash.confex.com/ash/2024/webprogram/Paper199913.html (American Society of Hematology, 2024).
Garfall, A. L. et al. Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. Blood Cancer Discov. 4118–133 (2023).
Google Scholar
Boccadoro, M. et al. DVRd followed by ciltacabtagene autoleucel versus DVRd followed by ASCT in patients with newly diagnosed multiple myeloma who are transplant eligible: a randomized phase 3 study (EMagine/CARTITUDE-6). Blood 1404630–4632 (2022).
Google Scholar
Rejeski, K. et al. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood 142865–877 (2023).
Google Scholar
Hines, M. R. et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant. Cell. Ther. 29438.e1–438.e16 (2023).
Google Scholar
Ellithi, M. et al. Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data. Transplant. Cell. Ther. 3171.e1–71.e14 (2025).
Google Scholar
Van Oekelen, O. et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Night. With. 272099–2103 (2021).
Google Scholar
Cohen, A. D. et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 1232 (2022).
Google Scholar
Fortuna, G. G. et al. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 14180 (2024).
Google Scholar
Yin, Q. et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front. Immunol. 141167975 (2023).
Google Scholar
Bansal, R. et al. Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma. Am. J. Hematol. 97E241–E244 (2022).
Google Scholar
Zhou, X. et al. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 1887 (2020).
Google Scholar
Jadlowsky, J. K. et al. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Night. With. 311134−1144 (2025).
Chen, J. P. et al. Reduced 2,4-dinitro-1-fluorobenzene-induced contact hypersensitivity response in IL-15 receptor α-deficient mice correlates with diminished CCL5/RANTES and CXCL10/IP-10 expression. Eur. J. Immunol. 35690–698 (2005).
Google Scholar
Gil, M., Park, S. J., Chung, Y. S. & Park, C. S. Interleukin-15 enhances proliferation and chemokine secretion of human follicular dendritic cells. Immunology 130536–544 (2010).
Google Scholar
Jin, P. et al. Synergistic enhancement of radio-immunotherapy efficacy by IL-15 via macrophage activation and memory T cell response. Cancer Lett. 613217511 (2025).
Google Scholar
Li, Y., Gao, H., Clark, K. M. & Shan, L. IL-15 enhances HIV-1 infection by promoting survival and proliferation of CCR5+CD4+ T cells. JCI Insight 8e166292 (2023).
Schechter, J. M. & Fan, X. BCMA-targeted CAR-T-cell therapy for multiple myeloma. World Intellectual Property Organization patent no. WO2023164695A2 (2023).
Campbell, T. et al. Uses of anti-BCMA chimeric antigen receptors. World Intellectual Property Organization patent no. PCT/US2020/058835 (2021).
Rosskopf, S. et al. A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies. Oncotarget 917608–17619 (2018).
Google Scholar
Atanackovic, D. et al. Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma. Nat. Common. 166154 (2025).
Google Scholar
Qu, FF et al. The CCL5/CCR5 axis in ulcerative colitis. Cell. Immunol. 407104891 (2025).
Google Scholar
Ghafouri-Fard, S., Shahir, M., Taheri, M. & Salimi, A. A review on the role of chemokines in the pathogenesis of systemic lupus erythematosus. Cytokine 146155640 (2021).
Google Scholar
Koski, H., Konttinen, YT, Hietanen, J., Tervo, T. & Malmström, M. Epidermal growth factor, Transforming growth factor-alpha, and epidermal growth factor receptor in labial salivary glands in Sjögren’s syndrome. J. Rheumatol. 241930–1935 (1997).
Google Scholar
Murayama, M. A., Shimizu, J., Miyabe, C., Yudo, K. & Miyabe, Y. Chemokines and chemokine receptors as promising targets in rheumatoid arthritis. Front. Immunol. 141100869 (2023).
Cook, S. et al. Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors. JAMA Netw. Open 7e2352302 (2024).
Google Scholar
Sullivan, R. J. et al. SITC vision: opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy. J. Immunother. Cancer 13e011929 (2025).
Alizadeh, D. et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol. Res. 7759–772 (2019).
Google Scholar
Ghilardi, G. et al. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines. Blood Adv. 8653–666 (2024).
Google Scholar
Tian, G. et al. Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15. J. Immunother. Cancer 13e010156 (2025).
Khandelwal, P. et al. CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study. Bone Marrow Transplant. 551552–1559 (2020).
Google Scholar
Reshef, R. et al. Extended CCR5 blockade for graft-versus-host disease prophylaxis improves outcomes of reduced-intensity unrelated donor hematopoietic cell transplantation: a phase II clinical trial. Biol. Blood Marrow Transplant. 25515–521 (2019).
Google Scholar
Lim, K. J. C. et al. Risk factors for delayed neurotoxicity in patients with relapsed myeloma who received ciltacabtagene autoleucel (cilta-cel). Transplant. Cell. Ther. 31S202 (2025).
Google Scholar
Pinto, S. N. & Krenciute, G. The mechanisms of altered blood−brain barrier permeability in CD19 CAR T-cell recipients. Int. J. Mol. Sci. 25644 (2024).
Haas, A. R. et al. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Mol. Ther. 312309–2325 (2023).
Google Scholar
Boulch, M. et al. A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy. Cell Rep. With. 4101161 (2023).
Google Scholar
James, C. A. et al. CD4 and CD8 co-receptors modulate functional avidity of CD1b-restricted T cells. Nat. Common. 1378 (2022).
Google Scholar
Lee, S. Y. et al. IL-12p40 homodimer ameliorates experimental autoimmune arthritis. J. Immunol. 1953001–3010 (2015).
Google Scholar
Marks, E. et al. Regulation of IL-12p40 by HIF controls Th1/Th17 responses to prevent mucosal inflammation. Mucosal Immunol. 101224–1236 (2017).
Google Scholar
Mondal, S. et al. IL-12 p40 monomer is different from other IL-12 family members to selectively inhibit IL-12Rβ1 internalization and suppress EAE. Proc. Natl Acad. Sci. USA 11721557–21567 (2020).
Google Scholar
Turner, J. et al. Prophylactic dexamethasone rescues unrestrained lymphocyte expansion in anti-BCMA chimeric antigen receptor T cell therapy in multiple myeloma. Transplant. Cell. Ther. 31S215−S216 (2025).
Costa, B. A. et al. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer J. 1484 (2024).
Google Scholar
mSMART. Stratification for Myeloma and Risk-Adapted Therapy. https://www.msmart.org/
Zanwar, S. et al. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia 36873–876 (2022).
Google Scholar
Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17e328–e346 (2016).
Google Scholar
Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 394073–4126 (2021).
Google Scholar
Huwaldt, J. A. PlotDigitizer. https://sourceforge.net/projects/plotdigitizer/ (2016).
Sherman, E. et al. INSPIIRED: a pipeline for quantitative analysis of sites of new DNA integration in cellular genomes. Mol. Ther. Methods Clin. Dev. 439–49 (2017).
Google Scholar
Berry, C. C. et al. INSPIIRED: quantification and visualization tools for analyzing integration site distributions. Mol. Ther. Methods Clin. Dev. 417–26 (2017).
Google Scholar
Nobles, C. L. et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J. Clin. Invest. 130673–685 (2020).
Google Scholar